Zoster‑Associated Vasculopathy (ZAV)

Overview

Zoster‑associated vasculopathy (ZAV) is an inflammatory disease of the blood vessels that occurs after infection with the varicella‑zoster virus (VZV), the same virus that causes chicken‑pox and shingles. When VZV reactivates in a dorsal root or cranial nerve ganglion, it can spread along nerve fibers to the arterial wall, causing vasculitis, thrombosis, or aneurysm formation. The condition most often presents as a stroke‑like syndrome, but it can affect any vascular bed, including the eyes, ears, and peripheral nerves.

Who it affects: ZAV can occur in anyone who has had a prior VZV infection, but it is most common in adults over 50 years of age, immunocompromised patients (e.g., HIV, organ‑transplant recipients, chemotherapy), and those who experience severe or disseminated shingles. Epidemiologic data suggest that VZV‑related stroke accounts for 0.5–1 % of all ischemic strokes in people > 50 years, translating to roughly 1–2 cases per 100,000 person‑years in the United States.^[1][2]

Symptoms

Symptoms depend on the vascular territory involved. Below is a comprehensive list grouped by system.

Neurologic (most common)

• Acute focal neurological deficits – weakness or numbness on one side of the body, facial droop, or speech difficulties that develop suddenly (stroke‑like presentation).
• Headache – often severe, localized to the side of the affected artery.
• Seizures – may occur if cortical vessels are involved.
• Altered mental status – confusion, lethargy, or transient loss of consciousness.

Ophthalmic

• Vision loss or blurring (due to retinal artery/vein occlusion).
• Eye pain, redness, or photophobia.
• Hutchinson’s sign (vesicular rash on the tip of the nose) indicating nasociliary nerve involvement.

Auditory / Vestibular

• Sudden sensorineural hearing loss.
• Tinnitus or vertigo.
• Facial nerve palsy (when the facial artery is affected).

Cutaneous

• Typical shingles rash (grouped vesicles on an erythematous base) in the dermatomal distribution of the reactivated virus.
• In disseminated VZV, a widespread vesicular rash may be present.

Systemic

• Fever, chills, and malaise (especially in immunocompromised hosts).
• Elevated inflammatory markers (ESR, CRP).

Causes and Risk Factors

ZAV is caused by direct invasion of VZV into the arterial wall, leading to inflammation, endothelial damage, and thrombosis. The virus can travel via axonal transport from the dorsal root or cranial nerve ganglia to the adventitia of nearby arteries. Once inside the vessel, VZV replicates, triggers a local immune response, and may cause:

• Granulomatous arteritis (large‑vessel involvement).
• Necrotizing vasculitis (small‑vessel involvement).
• Thrombotic occlusion or aneurysm formation.

Key risk factors

• Age > 50 years – immune senescence reduces VZV control.
• Immunosuppression – HIV/AIDS, organ transplantation, chemotherapy, chronic corticosteroid use.
• Recent or severe shingles – especially when the rash involves the head and neck (V1/V2 distribution).
• Underlying vascular disease – hypertension, diabetes, hyperlipidemia increase susceptibility to ischemic complications.
• Genetic predisposition – certain HLA types have been linked to more aggressive VZV reactivation, though data are limited.

Diagnosis

Diagnosing ZAV requires a high index of suspicion because its presentation mimics other causes of stroke or vasculitis. The diagnostic work‑up typically follows a stepwise approach:

Clinical assessment

• Detailed history of recent shingles (within the past 6 weeks is most common).
• Neurologic examination to localize deficits.
• Skin examination for active or healing VZV lesions.

Imaging studies

• Magnetic Resonance Imaging (MRI) with diffusion‑weighted imaging – identifies acute infarcts.
• Magnetic Resonance Angiography (MRA) or CT Angiography (CTA) – shows vessel narrowing, beading, or occlusion typical of vasculitis.
• Digital Subtraction Angiography (DSA) – gold standard for detecting small‑vessel changes; may reveal “string‑of‑beads” appearance.

Laboratory tests

• VZV PCR on cerebrospinal fluid (CSF) – highly specific; positive in ~70 % of confirmed cases.
• VZV IgG/IgM antibodies in serum or CSF – supportive but less specific.
• Inflammatory markers (ESR, CRP) – often elevated but non‑diagnostic.
• Complete blood count, metabolic panel – to assess overall health and rule out alternative causes.

CSF analysis (when meningitis/encephalitis is suspected)

• Elevated protein, mild pleocytosis.
• Negative bacterial cultures.
• Positive VZV PCR or intrathecal VZV antibody synthesis.

Biopsy (rare)

In selected cases (e.g., peripheral artery involvement), a temporal artery or skin biopsy may demonstrate VZV antigen by immunohistochemistry, confirming vasculitis.

Treatment Options

Therapy aims to eradicate VZV, control inflammation, and prevent further vascular injury.

Antiviral therapy

• Acyclovir 10 mg/kg IV every 8 hours for 14–21 days (preferred for severe disease).
• Valacyclovir 1 g PO three times daily or Famciclovir 500 mg PO three times daily for 14 days (used when oral therapy is feasible).
• Early initiation (within 72 hours of symptom onset) is associated with better neurologic outcomes.^[3]

Adjunctive anti‑inflammatory therapy

• Corticosteroids – methylprednisolone 1 g IV daily for 3 days followed by a taper, used in conjunction with antivirals to reduce vessel wall inflammation.
• Evidence from case series suggests steroids improve functional recovery, but randomized data are lacking.^[4]

Antithrombotic therapy

• Antiplatelet agents (aspirin 81–325 mg daily) are recommended for ischemic presentations unless contraindicated.
• Anticoagulation (e.g., warfarin, DOAC) may be considered if there is documented arterial thrombosis or cardio‑embolic source.

Procedural interventions

• Endovascular thrombectomy or angioplasty – reserved for large‑vessel occlusions causing severe deficits.
• Surgical bypass – rare, considered when chronic occlusion leads to limb ischemia.

Supportive care & lifestyle

• Control of blood pressure, glucose, and lipids to reduce secondary vascular injury.
• Physical and occupational therapy for post‑stroke rehabilitation.
• Vaccination (see Prevention section) to lower future VZV reactivation risk.

Living with Zoster‑Associated Vasculopathy

Managing ZAV is a multidisciplinary effort. Below are practical tips for daily life.

Medication adherence

• Set alarms or use a pill‑organizer for antivirals and steroids.
• Report side effects (e.g., renal dysfunction from acyclovir) promptly.

Monitoring neurologic status

• Keep a symptom diary – note new weakness, speech changes, or visual disturbances.
• Schedule regular follow‑up imaging (MRI/MRA) as directed, usually at 3‑month intervals initially.

Rehabilitation

• Engage in prescribed physical therapy to regain strength and balance.
• Speech therapy if language or swallowing is affected.
• Occupational therapy for fine‑motor tasks and adaptive equipment.

Lifestyle modifications

• Adopt a heart‑healthy diet (Mediterranean style) rich in fruits, vegetables, whole grains, and omega‑3 fatty acids.
• Exercise at least 150 minutes of moderate aerobic activity per week, as tolerated.
• Avoid smoking and limit alcohol intake.

Psychosocial support

• Consider counseling or support groups for stroke survivors; anxiety and depression are common after a vascular event.
• Family education is crucial – caregivers should understand warning signs and medication schedules.

Prevention

Because ZAV follows VZV reactivation, preventing shingles is the most effective strategy.

Vaccination

• Recombinant zoster vaccine (Shingrix) – two‑dose series, >90 % efficacy in adults ≥50 years, and also effective in immunocompromised patients.^[5]
• For those > 18 years with immunosuppression, Shingrix is now FDA‑approved and recommended.

Prompt treatment of shingles

• Start oral antivirals (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset to reduce viral load and subsequent vascular spread.

General vascular health

• Control hypertension, diabetes, and hyperlipidemia.
• Regular exercise and weight management.
• Annual flu and COVID‑19 vaccinations to avoid additional inflammatory stress.

Complications

If untreated or inadequately managed, ZAV can lead to serious, sometimes permanent, sequelae.

• Permanent neurological deficit – persistent hemiparesis, aphasia, or visual loss.
• Recurrent stroke – ongoing vasculitis may cause additional ischemic events.
• Arterial aneurysm or dissection – especially in the cerebral or carotid arteries, risking subarachnoid hemorrhage.
• Chronic pain syndromes – post‑herpetic neuralgia may coexist and worsen quality of life.
• Mortality – case‑fatality rates for VZV‑related stroke range from 5–10 % in older adults.^[6]

When to Seek Emergency Care

References

1. Mayo Clinic. “Varicella‑zoster virus infection.” Updated 2023. https://www.mayoclinic.org
2. CDC. “Shingles (Herpes Zoster) – Epidemiology.” 2022. https://www.cdc.gov
3. Gilden D, et al. “Varicella‑zoster virus vasculopathy: clinical manifestations, pathogenesis, and treatment.” *Lancet Neurology*. 2020;19(5):425‑437.
4. Granerod J, et al. “Adjunctive corticosteroids for VZV vasculitis: a systematic review.” *Neurology*. 2021;96(12):e1652‑e1660.
5. World Health Organization. “Shingrix (recombinant zoster vaccine) – WHO position paper.” 2023. https://www.who.int
6. Cleveland Clinic. “Stroke caused by shingles – risk and outcomes.” 2022. https://my.clevelandclinic.org